Paper Details

  1. Home
  2. Paper Details

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.

Author: AltenRieke E, BurmesterGerd-Rüdiger, CatrinaAnca Irinel, ConaghanPhilip G, DiCarloJulie, DurezPatrick, GaillezCorine, KlareskogLars, Le BarsManuela, PeterfyCharles, TakPaul P, ZhouXianhuang

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Abatacept treatment for rheumatoid arthritis showed structural and synovial benefit, sustained to Month 12. MRI detected significant improvements in synovitis, osteitis, and erosion.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: This randomised, double-blind, placebo-controlled phase IIIb study evaluated the impact of abatacept on MRI pathology as a primary outcome in methotrexate (MTX)-refractory patients with rheumatoid arthritis. METHODS: Patients received intravenous abatacept (∼10 mg/kg) or placebo, on bac...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711370/

データ提供：米国国立医学図書館（NLM）

Abatacept: A New Oasis in the Desert of Rheumatoid Arthritis

Rheumatoid arthritis (RA), a chronic autoimmune disease, can feel like a relentless desert storm, causing pain, inflammation, and joint damage. This study explores the impact of abatacept, a biological therapy, on the progression of RA in patients who have not responded adequately to methotrexate (MTX). The researchers, like skilled desert navigators, meticulously analyze the results of a randomized controlled trial, comparing the effects of abatacept to a placebo in patients with RA. Their goal is to find a way to mitigate the destructive effects of RA, offering a potential oasis in the desert of this debilitating condition.

A New Path to Relief

The study reveals that abatacept, like a refreshing spring in the desert, showed a significant benefit in reducing synovitis, osteitis, and erosion in patients with RA. This finding suggests that abatacept may help slow the progression of RA and potentially alleviate the pain and discomfort associated with this condition. This research underscores the importance of personalized treatment approaches and the potential of biological therapies to improve outcomes for patients with RA.

Navigating the Desert of RA Treatment

This study, like a compass guiding us through the desert of RA treatment, offers a glimpse into the potential of abatacept as a promising new therapy. It highlights the importance of tailoring treatment approaches to meet the unique needs of each patient. This research encourages continued exploration of novel therapies to improve the lives of individuals with RA, offering hope for a brighter future in the face of this challenging condition.

Dr.Camel's Conclusion

This study, like a well in the desert of rheumatoid arthritis, offers a promising new path to relief for patients who have not responded well to conventional treatments. It reminds us that innovation and personalized care are essential in addressing the challenges of chronic autoimmune diseases.

Date :
  1. Date Completed 2013-09-19
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

22915624

DOI: Digital Object Identifier

PMC3711370

Related Literature

Article Analysis
・Effects of abatacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.